Tryptamine Therapeutics (ASX:TYP) - Stock Price, News & Analysis

TYP Stock Overview

Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States.

About the company

TYP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 2% per year over the past 5 years

Risk Analysis

Negative shareholders equity

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (CA$0)

Does not have a meaningful market cap (A$29M)

Tryptamine Therapeutics Limited Competitors

Little Green Pharma

ASX:LGP

AU$29.9m

Invion

ASX:IVX

AU$26.4m

Starpharma Holdings

ASX:SPL

AU$39.6m

Medical Developments International

ASX:MVP

AU$41.9m

Price History & Performance

Summary of all time highs, changes and price drops for Tryptamine Therapeutics
Historical stock prices
Current Share Price	AU$0.02
52 Week High	AU$0.027
52 Week Low	AU$0.018
Beta	0
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-23.08%

Recent updates

Shareholder Returns

	TYP	AU Pharmaceuticals	AU Market
7D	-9.1%	-1.4%	-2.2%
1Y	n/a	63.4%	5.4%

Return vs Industry: Insufficient data to determine how TYP performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how TYP performed against the Australian Market.

Price Volatility

Is TYP's price volatile compared to industry and market?
TYP volatility
TYP Average Weekly Movement	11.7%
Pharmaceuticals Industry Average Movement	10.3%
Market Average Movement	8.1%
10% most volatile stocks in AU Market	16.4%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: TYP's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine TYP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	n/a	Jason Carroll	www.tryptherapeutics.com

Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company’s program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications.

Tryptamine Therapeutics Limited Fundamentals Summary

How do Tryptamine Therapeutics's earnings and revenue compare to its market cap?
TYP fundamental statistics
Market cap	AU$30.74m
Earnings (TTM)	-AU$4.97m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-5.9x

P/E Ratio

Is TYP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TYP income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$4.49m
Earnings	-CA$4.49m

Last Reported Earnings

Feb 29, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0031
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-90.5%

How did TYP perform over the long term?

See historical performance and comparison

Tryptamine Therapeutics ASX:TYP Stock Report